ECSP12012056A - Derivados de 3-hidroxi-5-arilisotiazol novedosos - Google Patents

Derivados de 3-hidroxi-5-arilisotiazol novedosos

Info

Publication number
ECSP12012056A
ECSP12012056A ECSP12012056A ECSP12012056A EC SP12012056 A ECSP12012056 A EC SP12012056A EC SP12012056 A ECSP12012056 A EC SP12012056A EC SP12012056 A ECSP12012056 A EC SP12012056A
Authority
EC
Ecuador
Prior art keywords
compound
ring
salt
novedosos
arilisotiazol
Prior art date
Application number
Other languages
English (en)
Inventor
Naoto Kosuga
Daido Hotta
Akihiro Okano
Muneyoshi Makabe
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of ECSP12012056A publication Critical patent/ECSP12012056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Proporcionar un agente que activa GPR40 que tiene, como un ingrediente activo, un compuesto novedoso que tiene una acción agonista GPR40, una sal del compuesto, un solvato de la sal o el compuesto, o similares, particularmente, un secretagogo de insulina y y un agente terapéutico y/o profiláctico contra diabetes, obesidad, u otras enfermedades.Medios para solucionar el problemaUn compuesto de la Fórmula (I): donde n es 0 hasta 2; p es 0 hasta 4; j es 0 hasta 3; k es 0 hasta 2; un anillo A es un grupo arilo que está opcionalmente sustituido con L o un grupo heterocíclico que está opcionalmente sustituido con L; un anillo B es un anillo de benceno, un anillo de piridina, o un anillo de pirimidina;X es O, S, -NR7-; y R1 hasta R7 son grupos específicos,una sal del compuesto, o un solvato de la sal o el compuesto.
ECSP12012056 2009-12-25 2012-07-23 Derivados de 3-hidroxi-5-arilisotiazol novedosos ECSP12012056A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009295855 2009-12-25
JP2010043420 2010-02-26

Publications (1)

Publication Number Publication Date
ECSP12012056A true ECSP12012056A (es) 2012-10-30

Family

ID=44195895

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012056 ECSP12012056A (es) 2009-12-25 2012-07-23 Derivados de 3-hidroxi-5-arilisotiazol novedosos

Country Status (25)

Country Link
US (1) US8476287B2 (es)
EP (1) EP2518060A4 (es)
JP (2) JP5002077B2 (es)
KR (1) KR20130004262A (es)
CN (2) CN104710381A (es)
AU (1) AU2010336225A1 (es)
BR (1) BR112012015612A2 (es)
CA (1) CA2785674A1 (es)
CL (1) CL2012001722A1 (es)
CO (1) CO6650337A2 (es)
CR (1) CR20120345A (es)
EA (1) EA201290574A1 (es)
EC (1) ECSP12012056A (es)
GT (1) GT201200217A (es)
HN (1) HN2012001351A (es)
IL (1) IL220616A0 (es)
MA (1) MA33952B1 (es)
MX (1) MX2012007474A (es)
NI (1) NI201200113A (es)
NZ (1) NZ601408A (es)
PE (1) PE20121639A1 (es)
RU (1) RU2567755C2 (es)
SG (1) SG181961A1 (es)
WO (1) WO2011078371A1 (es)
ZA (1) ZA201203416B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052756A1 (ja) 2009-10-30 2011-05-05 持田製薬株式会社 新規３－ヒドロキシ－５－アリールイソキサゾール誘導体
JP5002077B2 (ja) 2009-12-25 2012-08-15 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソチアゾール誘導体
US8581584B2 (en) * 2010-05-26 2013-11-12 Florida State University Research Foundation Membrane proteins, mechanisms of action and uses thereof
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
ES2652662T3 (es) 2011-02-25 2018-02-05 Merck Sharp & Dohme Corp. Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos
JP5420796B2 (ja) * 2011-04-27 2014-02-19 持田製薬株式会社 新規３−ヒドロキシイソチアゾール１−オキシド誘導体
AU2012248627A1 (en) * 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013154163A1 (ja) * 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
CN106977495B (zh) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 Dna-pk抑制剂
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
ES2900061T3 (es) 2013-03-12 2022-03-15 Vertex Pharma Inhibidores de DNA-PK
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3424920B1 (en) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
AP2016009176A0 (en) 2013-11-14 2016-04-30 Cadila Healthcare Ltd Novel heterocyclic compounds
CN107708690B (zh) * 2015-02-27 2021-09-14 常山凯捷健生物药物研发（河北）有限公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MX2020008404A (es) 2018-02-13 2020-09-25 Gilead Sciences Inc Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
CN110066254B (zh) * 2018-11-16 2021-03-19 温州大学 一种异噻唑-3-酮化合物的制备方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
EP4153589A1 (en) 2020-05-19 2023-03-29 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115433143B (zh) * 2021-06-03 2023-10-13 中国科学院大连化学物理研究所 一种异噻唑啉酮类化合物的合成方法
CN115386028B (zh) * 2022-08-26 2023-06-23 长春理工大学 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562283A (en) 1968-07-01 1971-02-09 Rohm & Haas 1-oxo and 1,1-dioxo-3-isothiazolones
US3801575A (en) * 1972-01-24 1974-04-02 Rohm & Haas 3-hydroxyisothiazoles
RU2165415C2 (ru) 1996-02-27 2001-04-20 Санкио Компани Лимитед Производные изоксазола и фармацевтическая композиция на их основе
CN1149204C (zh) 1999-01-13 2004-05-12 沃尼尔·朗伯公司 1-杂环取代的二芳基胺
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
WO2004011446A1 (en) 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
WO2004022551A1 (ja) 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited フランまたはチオフェン誘導体およびその医薬用途
EP2385032A1 (en) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
JP4594611B2 (ja) 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
WO2005035551A2 (en) * 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
MX2008001386A (es) 2005-08-10 2008-04-07 Takeda Pharmaceutical Agente terapeutico para diabetes.
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
WO2008033931A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
US8367708B2 (en) 2006-12-01 2013-02-05 Msd K.K. Phenyl-isoxazol-3-ol derivative
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
RU2488578C2 (ru) 2007-09-21 2013-07-27 Санофи-Авентис (карбоксилалкиленфенил) фенилоксаламиды, способ их получения и их применение в качестве лекарственного средства
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
US20110065739A1 (en) 2008-06-02 2011-03-17 Makoto Ishikawa Novel isoxazole drivative
CN102076650A (zh) 2008-06-25 2011-05-25 第一三共株式会社 羧酸化合物
CA2749930A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
EP2393810A1 (en) 2009-02-05 2011-12-14 Schering Corporation Phthalazine-containing antidiabetic compounds
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
WO2011052756A1 (ja) 2009-10-30 2011-05-05 持田製薬株式会社 新規３－ヒドロキシ－５－アリールイソキサゾール誘導体
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
JP5002077B2 (ja) 2009-12-25 2012-08-15 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソチアゾール誘導体
CN101781268B (zh) 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体

Also Published As

Publication number Publication date
EP2518060A1 (en) 2012-10-31
CN102712610B (zh) 2015-03-04
US20120157459A1 (en) 2012-06-21
JP2012153726A (ja) 2012-08-16
HN2012001351A (es) 2015-03-23
US8476287B2 (en) 2013-07-02
MX2012007474A (es) 2012-08-01
NI201200113A (es) 2012-08-13
KR20130004262A (ko) 2013-01-09
JP5002077B2 (ja) 2012-08-15
AU2010336225A1 (en) 2012-08-16
CO6650337A2 (es) 2013-04-15
CL2012001722A1 (es) 2012-12-14
RU2567755C2 (ru) 2015-11-10
PE20121639A1 (es) 2012-12-02
GT201200217A (es) 2014-02-10
SG181961A1 (en) 2012-08-30
MA33952B1 (fr) 2013-01-02
WO2011078371A1 (ja) 2011-06-30
EA201290574A1 (ru) 2012-12-28
CN102712610A (zh) 2012-10-03
RU2012131840A (ru) 2014-01-27
CA2785674A1 (en) 2011-06-30
CN104710381A (zh) 2015-06-17
JPWO2011078371A1 (ja) 2013-05-09
IL220616A0 (en) 2012-08-30
ZA201203416B (en) 2013-08-28
CR20120345A (es) 2012-11-01
EP2518060A4 (en) 2014-01-08
NZ601408A (en) 2013-12-20
BR112012015612A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
ECSP12012056A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
BR112013027883A2 (pt) novo derivado de 1-óxido de 3-hidroxiisotiazol
NI201700135A (es) Derivados de ciclohexano sustituido con amido
CO2017006308A2 (es) Derivados de glucagón
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
UA114710C2 (uk) Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
CR10564A (es) Compuestos cíclicos fusionados
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
EA201201648A1 (ru) Стимуляторы sgc
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
PE20140244A1 (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
CR20120296A (es) Nuevos compuestos de espiropiperidina
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
PE20130815A1 (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos
PA8846201A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
UY36060A (es) Compuestos de azol sustituidos con amida
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PH12018550212A1 (en) Rotigotine behenate and preparation method and use thereof